Literature DB >> 1206436

Folate and monoamine metabolism in epilepsy.

E H Reynolds, D Chadwick, P Jenner, I Chanarin.   

Abstract

In 27 drug-treated epileptics there was a significant fall in serum, red cell and CSF folate levels compared with 15 untreated epileptics and 22 neurological controls. The 3 folate parameters were positively correlated with each other and negatively correlated with serum phenobarbitone, diphenylhydantoin and primidone. There was also a significant elevation of CSF 5-hydroxyindoleacetic acid (5HIAA) in the drug-treated epileptics; but this was not seen until "therapeutic" serum levels of phenobarbitone and diphenylhydantoin had been achieved and was most marked in clinically intoxicated patients. Similar trends were observed in CSF homovanillic acid (HVA). CSF 5HIAA and HVA were positively correlated with each other, especially in the drug-treated patients, in whom both amine metabolites were also negatively correlated with CSF folate. A possible relationship between folate and monoamine metabolism is discussed with particular reference to the antiepileptic and toxic effects of phenobarbitone, diphenylhydantoin and primidone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1206436     DOI: 10.1016/0022-510x(75)90063-5

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Folate and depression--a neglected problem.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

Review 2.  Drugs and folate metabolism.

Authors:  D G Lambie; R H Johnson
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

3.  Thiamine deficiency and cerebrospinal fluid 5-hydroxyindoleacetic acid: a preliminary study.

Authors:  M I Botez; S N Young; J Bachevalier; S Gauthier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-08       Impact factor: 10.154

Review 4.  Serotonin and sudden unexpected death in epilepsy.

Authors:  Alexandra N Petrucci; Katelyn G Joyal; Benton S Purnell; Gordon F Buchanan
Journal:  Exp Neurol       Date:  2019-12-19       Impact factor: 5.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.